Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen B Fox

Showing results (191-200 of 258) with videos related to

Pageof 26
Sort By:
Breast Cancer Research : BCR|April 8, 2026
Transcriptomic deconvolution reveals prognostic immune signatures and immunotherapy-responsive subtypes in male breast cancerValentina Silvestri, Virginia Valentini, Agostino Bucalo, et al.
Breast Cancer Research and Treatment|January 29, 2014
Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy"Chiara Foroni, Manuela Milan, Carla Strina, et al.
NPJ Breast Cancer|March 21, 2020
The genetic architecture of breast papillary lesions as a predictor of progression to carcinomaTanjina Kader, Kenneth Elder, Magnus Zethoven, et al.
Molecular Diagnosis & Therapy|November 11, 2025
Clinical Utility of an RNA-based Gene Fusion Assay in Sarcoma for Diagnosis and Management: Experience in an Australian LaboratoryAdel Shahnam, Catherine Mitchell, Christopher R McEvoy, et al.
The Journal of Pathology|March 8, 2019
Atypical ductal hyperplasia is a multipotent precursor of breast carcinomaTanjina Kader, Prue Hill, Magnus Zethoven, et al.
Pathology|July 4, 2017
Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancyFedaa Najdawi, Ashley Crook, Jayne Maidens, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|September 3, 2020
A MXI1-NUTM1 fusion protein with MYC-like activity suggests a novel oncogenic mechanism in a subset of NUTM1-rearranged tumorsChristopher R McEvoy, Holly Holliday, Niko Thio, et al.
Breast Cancer Research : BCR|September 1, 2010
Breast cancer prognostic classification in the molecular era: the role of histological gradeEmad A Rakha, Jorge S Reis-Filho, Frederick Baehner, et al.
The Oncologist|June 20, 2020
ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance ProfilingMalinda Itchins, Brandon Lau, Amanda L Hudson, et al.
Pigment Cell & Melanoma Research|February 6, 2014
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell linesRichard J Young, Kelly Waldeck, Claire Martin, et al.
Pageof 26

Showing results (191-200 of 258) with videos related to

Sort By:
Pageof 26
Breast Cancer Research : BCR|April 8, 2026
Transcriptomic deconvolution reveals prognostic immune signatures and immunotherapy-responsive subtypes in male breast cancerValentina Silvestri, Virginia Valentini, Agostino Bucalo, et al.
Breast Cancer Research and Treatment|January 29, 2014
Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy"Chiara Foroni, Manuela Milan, Carla Strina, et al.
NPJ Breast Cancer|March 21, 2020
The genetic architecture of breast papillary lesions as a predictor of progression to carcinomaTanjina Kader, Kenneth Elder, Magnus Zethoven, et al.
Molecular Diagnosis & Therapy|November 11, 2025
Clinical Utility of an RNA-based Gene Fusion Assay in Sarcoma for Diagnosis and Management: Experience in an Australian LaboratoryAdel Shahnam, Catherine Mitchell, Christopher R McEvoy, et al.
The Journal of Pathology|March 8, 2019
Atypical ductal hyperplasia is a multipotent precursor of breast carcinomaTanjina Kader, Prue Hill, Magnus Zethoven, et al.
Pathology|July 4, 2017
Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancyFedaa Najdawi, Ashley Crook, Jayne Maidens, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|September 3, 2020
A MXI1-NUTM1 fusion protein with MYC-like activity suggests a novel oncogenic mechanism in a subset of NUTM1-rearranged tumorsChristopher R McEvoy, Holly Holliday, Niko Thio, et al.
Breast Cancer Research : BCR|September 1, 2010
Breast cancer prognostic classification in the molecular era: the role of histological gradeEmad A Rakha, Jorge S Reis-Filho, Frederick Baehner, et al.
The Oncologist|June 20, 2020
ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance ProfilingMalinda Itchins, Brandon Lau, Amanda L Hudson, et al.
Pigment Cell & Melanoma Research|February 6, 2014
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell linesRichard J Young, Kelly Waldeck, Claire Martin, et al.
Pageof 26